As Congress Stalls on Data Privacy, Americans Lose Out

2022 promised great things for data privacy. High-profile cyberattacks and a bipartisan consensus that Congress ought to act had commentators predicting a federal data standard was a real possibility. However, political headwinds, midterms, and other priorities have conspired against such a standard, and prospects now appear remote. Unfortunately, Americans lose out without a unified federal […]

Consumers Would Benefit from State Bans on Copay Adjustment Programs

Last month, the Ohio House Legislature voted unanimously 89-0 to end a controversial practice known as accumulator adjustment, or copay adjustment, that Pharmacy Benefit Managers (PBMs) and insurance companies use to restrict patient access to drug manufacturers provided copay coupons used to help meet their deductibles. Should the bill be approved by the Ohio Senate, […]

The Economic Standard: Would Microsoft’s Proposed Activision Merger Be Positive for Consumers?

By now, most people will have heard about Microsoft Corporation’s intension to purchase gaming giant and interactive content publisher Activision Blizzard Inc. in what is already being called the largest tech deal ever. While some may have concerns about the size of the merger, the deal could well be a major victory for consumers and […]

Study Reveals How Price Controls Harmed Biopharma Industry in Europe

Europe has long taken a stricter regulatory approach to the Pharmaceutical industry than the U.S. Nowhere is this more apparent than in the area of price controls. Europe has been zealous in its application of price-caps on prescription medicines in an effort to hold down drug prices. Unfortunately, these policies frequently lead to sharp declines […]

Inside Sources: Risk-Based Legislation Offers Better Alternatives to Tobacco Products

Lawmakers should take lessons from their policy failures and seek to avoid more restrictive measures like those guiding the FDA application process. Instead, lawmakers should support legislation that is risk-proportionate and flexible to the diverse preferences of consumers. This will go a long way toward preventing unintended consequences, improving public health and protecting consumer choice. […]

ACI Files Comments with FTC and DOJ on Their Request for Information on Merger Enforcement

The Federal Trade Commission (FTC) and Antitrust Division of the Department of Justice (DOJ) are seeking information on how the agencies can modernize enforcement of the antitrust laws regarding mergers. Today, ACI filed its comments for this request for Information — available here.

Can JetBlue’s Deal with Spirit Increase Competition and Consumer Benefits?

JetBlue Airlines made an unexpected $3.6 Billion bid to purchase Spirit Airlines this week, in a move that, some believe, could bring welcome competition to the airline industry and benefit consumers. The airline industry has come a long way since the days of public ownership. Following the passage of the Airline Deregulation Act of 1978, […]

ACI Files Comments with the FTC Regarding PBM Business Practices and their Impact on Drug Prices

The Federal Trade Commission is currently collecting public comments on the “Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers.” Today ACI filed its comments with the FTC. The comments are available here.

Pharmacy Benefit Managers Drive High Drug Prices

Most consumers are probably aware of the growing problem of high drug prices in America today. From the high cost of drugs needed for everyday ailments, to specific prescription plans that require expensive copays and deductibles, Americans pay an unnecessarily high price for their medication. However, what they are probably unaware of is how Pharmacy […]